Kyle Bass and Erich Spangenberg, the men behind a crusade challenging the validity of more than 30 pharmaceutical patents, have convinced the U.S. Patent and Trademark Office to institute reviews of two more drug patents.
Monday’s decisions mean that, to date, their Coalition for Affordable Drugs has persuaded the PTO’s Patent Trial and Appeal Board to hear 54 percent of the inter partes review challenges it has filed. The PTAB institutes a review, which is like a minitrial, when it is convinced the challenge shows a “reasonable likelihood of success.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
